Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2025

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following (in thousands): 

	As of
	June 30, 2025		December 31, 2024
Salaries and benefits	$	83,464	$	60,815
Incentive compensation	42,796		59,445
Deferred revenue	21,919		30,358
Italy medical device payback provision(1)	29,287		23,937
Field service corrective action(2)	25,488		32,844
Other	110,844		99,524
	$	313,798	$	306,923

___________________________

(1)     Related to potential payments associated with the IMDP (as defined below) as a result of 2015 legislation enacted requiring medical device companies to make payments to the Italian government based on regional expenditure ceilings (see Note 20: Commitments and Contingencies for further details).

(2)     Primarily includes field corrective actions associated with certain products in connection with a 2021 Warning Letter (as defined below) received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility (see Note 20: Commitments and Contingencies for further details).

As of December 31, 2024, certain accrued liability account balances that were part of a disposal group that met the criteria for assets held for sale during the fourth quarter of 2024 were presented as a separate line item "Liabilities held for sale" in our consolidated balance sheet (See Note 4:Assets Held For Sale and Disposal of Business).